Psychiatric Uses of Beta-blockers
Abstract Beta-blocking agents have been used for many years in psychiatry. But many are suspicious about their mechanisms and therapeutic effects. In this review, the most part of clinical trials is reported and criticized. With the exception of anxiolytic effects, the other therapeutic effects are...
Gespeichert in:
| Veröffentlicht in: | Pharmacopsychiatry 1980-09, Vol.13 (5), p.267-272 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 272 |
|---|---|
| container_issue | 5 |
| container_start_page | 267 |
| container_title | Pharmacopsychiatry |
| container_volume | 13 |
| creator | Cuche, H. Deniker, P. |
| description | Abstract
Beta-blocking agents have been used for many years in psychiatry. But many are suspicious about their mechanisms and therapeutic effects. In this review, the most part of clinical trials is reported and criticized. With the exception of anxiolytic effects, the other therapeutic effects are still questionable for many reasons, such as the methodology of clinical trials.
In this paper, others agents which interact with the noradrenergic system are envisaged. It is taking into account all these factors (alpha and beta receptors, alpha and beta agents) that we can looking forward for a real progress in the field of biochemical psychiatry. |
| doi_str_mv | 10.1055/s-2007-1019644 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1055_s_2007_1019644</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>6108581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c328t-7c6fa45452de4f4b2f4a64e740222ef34c61d0e4ea3ca251198edc6f3ef4d56d3</originalsourceid><addsrcrecordid>eNp1j01PAjEURRujQUS37kzwBxTfa187M0slfiUkupB1UzqvYRAc0g4L_r1DIO5c3cW95yZHiFuECYIxD1kqgEIiYGWJzsQQSVcSisqciyFgYaW2RXUprnJeASBVoAdiYBFKU-JQ3H_mfVg2vktNGM8z53Ebx0_ceblYt-GbU74WF9GvM9-cciTmL89f0zc5-3h9nz7OZNCq7GQRbPRkyKiaKdJCRfKWuCBQSnHUFCzWwMReB68MYlVy3TOaI9XG1nokJsffkNqcE0e3Tc3Gp71DcAdVl91B1Z1Ue-DuCGx3iw3Xf_OTW9_LY98tG96wW7W79NMb_Pf3C9-FW2Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Psychiatric Uses of Beta-blockers</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>Cuche, H. ; Deniker, P.</creator><creatorcontrib>Cuche, H. ; Deniker, P.</creatorcontrib><description>Abstract
Beta-blocking agents have been used for many years in psychiatry. But many are suspicious about their mechanisms and therapeutic effects. In this review, the most part of clinical trials is reported and criticized. With the exception of anxiolytic effects, the other therapeutic effects are still questionable for many reasons, such as the methodology of clinical trials.
In this paper, others agents which interact with the noradrenergic system are envisaged. It is taking into account all these factors (alpha and beta receptors, alpha and beta agents) that we can looking forward for a real progress in the field of biochemical psychiatry.</description><identifier>ISSN: 0176-3679</identifier><identifier>ISSN: 0031-7098</identifier><identifier>EISSN: 1439-0795</identifier><identifier>DOI: 10.1055/s-2007-1019644</identifier><identifier>PMID: 6108581</identifier><language>eng</language><publisher>Germany</publisher><subject>Adrenergic beta-Antagonists - adverse effects ; Adrenergic beta-Antagonists - therapeutic use ; Anxiety - drug therapy ; Humans ; Mental Disorders - drug therapy ; Psychotic Disorders - drug therapy ; Recurrence ; Schizophrenia - drug therapy</subject><ispartof>Pharmacopsychiatry, 1980-09, Vol.13 (5), p.267-272</ispartof><rights>Georg Thieme Verlag KG Stuttgart · New York</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c328t-7c6fa45452de4f4b2f4a64e740222ef34c61d0e4ea3ca251198edc6f3ef4d56d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-2007-1019644.pdf$$EPDF$$P50$$Gthieme$$H</linktopdf><link.rule.ids>314,780,784,3015,3016,27922,27923,54557</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6108581$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cuche, H.</creatorcontrib><creatorcontrib>Deniker, P.</creatorcontrib><title>Psychiatric Uses of Beta-blockers</title><title>Pharmacopsychiatry</title><addtitle>Pharmacopsychiatry</addtitle><description>Abstract
Beta-blocking agents have been used for many years in psychiatry. But many are suspicious about their mechanisms and therapeutic effects. In this review, the most part of clinical trials is reported and criticized. With the exception of anxiolytic effects, the other therapeutic effects are still questionable for many reasons, such as the methodology of clinical trials.
In this paper, others agents which interact with the noradrenergic system are envisaged. It is taking into account all these factors (alpha and beta receptors, alpha and beta agents) that we can looking forward for a real progress in the field of biochemical psychiatry.</description><subject>Adrenergic beta-Antagonists - adverse effects</subject><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Anxiety - drug therapy</subject><subject>Humans</subject><subject>Mental Disorders - drug therapy</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Recurrence</subject><subject>Schizophrenia - drug therapy</subject><issn>0176-3679</issn><issn>0031-7098</issn><issn>1439-0795</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1980</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1j01PAjEURRujQUS37kzwBxTfa187M0slfiUkupB1UzqvYRAc0g4L_r1DIO5c3cW95yZHiFuECYIxD1kqgEIiYGWJzsQQSVcSisqciyFgYaW2RXUprnJeASBVoAdiYBFKU-JQ3H_mfVg2vktNGM8z53Ebx0_ceblYt-GbU74WF9GvM9-cciTmL89f0zc5-3h9nz7OZNCq7GQRbPRkyKiaKdJCRfKWuCBQSnHUFCzWwMReB68MYlVy3TOaI9XG1nokJsffkNqcE0e3Tc3Gp71DcAdVl91B1Z1Ue-DuCGx3iw3Xf_OTW9_LY98tG96wW7W79NMb_Pf3C9-FW2Q</recordid><startdate>198009</startdate><enddate>198009</enddate><creator>Cuche, H.</creator><creator>Deniker, P.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>198009</creationdate><title>Psychiatric Uses of Beta-blockers</title><author>Cuche, H. ; Deniker, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c328t-7c6fa45452de4f4b2f4a64e740222ef34c61d0e4ea3ca251198edc6f3ef4d56d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1980</creationdate><topic>Adrenergic beta-Antagonists - adverse effects</topic><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Anxiety - drug therapy</topic><topic>Humans</topic><topic>Mental Disorders - drug therapy</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Recurrence</topic><topic>Schizophrenia - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cuche, H.</creatorcontrib><creatorcontrib>Deniker, P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pharmacopsychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cuche, H.</au><au>Deniker, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psychiatric Uses of Beta-blockers</atitle><jtitle>Pharmacopsychiatry</jtitle><addtitle>Pharmacopsychiatry</addtitle><date>1980-09</date><risdate>1980</risdate><volume>13</volume><issue>5</issue><spage>267</spage><epage>272</epage><pages>267-272</pages><issn>0176-3679</issn><issn>0031-7098</issn><eissn>1439-0795</eissn><abstract>Abstract
Beta-blocking agents have been used for many years in psychiatry. But many are suspicious about their mechanisms and therapeutic effects. In this review, the most part of clinical trials is reported and criticized. With the exception of anxiolytic effects, the other therapeutic effects are still questionable for many reasons, such as the methodology of clinical trials.
In this paper, others agents which interact with the noradrenergic system are envisaged. It is taking into account all these factors (alpha and beta receptors, alpha and beta agents) that we can looking forward for a real progress in the field of biochemical psychiatry.</abstract><cop>Germany</cop><pmid>6108581</pmid><doi>10.1055/s-2007-1019644</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0176-3679 |
| ispartof | Pharmacopsychiatry, 1980-09, Vol.13 (5), p.267-272 |
| issn | 0176-3679 0031-7098 1439-0795 |
| language | eng |
| recordid | cdi_crossref_primary_10_1055_s_2007_1019644 |
| source | MEDLINE; Thieme Connect Journals |
| subjects | Adrenergic beta-Antagonists - adverse effects Adrenergic beta-Antagonists - therapeutic use Anxiety - drug therapy Humans Mental Disorders - drug therapy Psychotic Disorders - drug therapy Recurrence Schizophrenia - drug therapy |
| title | Psychiatric Uses of Beta-blockers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A25%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psychiatric%20Uses%20of%20Beta-blockers&rft.jtitle=Pharmacopsychiatry&rft.au=Cuche,%20H.&rft.date=1980-09&rft.volume=13&rft.issue=5&rft.spage=267&rft.epage=272&rft.pages=267-272&rft.issn=0176-3679&rft.eissn=1439-0795&rft_id=info:doi/10.1055/s-2007-1019644&rft_dat=%3Cpubmed_cross%3E6108581%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6108581&rfr_iscdi=true |